(Cholangiocarcinoma) Is Pemigatinib Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
On February 14, 2022, Vivek Subbiah et al. from The University of Texas MD Anderson Cancer Center published results from the FIGHT-101 Phase 1/2 clinical trial in the medical journal Annals of Oncology, evaluating the efficacy and safety of the FGFR inhibitor Pemigatinib in patients with advanced malignant tumors harboring FGF/FGFR gene alterations.
The FIGHT-101 Phase 1/2 clinical trial enrolled patients with advanced malignant tumors harboring FGF/FGFR gene alterations (N=128) and divided them into two groups: one group received Pemigatinib 1–20 mg once daily for two weeks followed by one week off (N=70), and the other group received Pemigatinib 1–20 mg once daily on a continuous schedule (N=58). The primary endpoint was dose-limiting toxicity.
The results showed that no dose-limiting toxicity was confirmed in the primary endpoint. The recommended Phase 2 dose was determined to be Pemigatinib 13.5 mg once daily. The most commonly observed adverse event was hyperphosphatemia in 75.0% of patients (Grade 3 or higher: 2.3%), with fatigue being the most frequent Grade 3 or higher adverse event at 10.2%.
In terms of efficacy, 12 patients achieved partial responses, including 5 with cholangiocarcinoma and one each with head and neck cancer, pancreatic cancer, gallbladder cancer, cervical cancer, urothelial cancer, non-small cell lung cancer, and pilocytic astrocytoma. The median duration of treatment was 7.3 months.
Based on the FIGHT-101 trial results, Vivek Subbiah et al. stated: "Antitumor responses were confirmed in patients with advanced malignant tumors harboring FGF/FGFR gene alterations treated with the FGFR inhibitor Pemigatinib. These results have supported subsequent Phase 2/3 clinical trials in cholangiocarcinoma and other multiple cancer types."
Source: https://www.annalsofoncology.org/article/S0923-7534(22)00110-7/fulltext
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4